These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 34959980)

  • 61. Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.
    Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Tanaka H; Tamai T; Koizumi Y; Hiasa Y; Michitaka K; Kudo M; ;
    Oncology; 2019; 97(5):277-285. PubMed ID: 31307035
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses.
    Tamai T; Hayato S; Hojo S; Suzuki T; Okusaka T; Ikeda K; Kumada H
    J Clin Pharmacol; 2017 Sep; 57(9):1138-1147. PubMed ID: 28561918
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Sorafenib
    Kuzuya T; Ishigami M; Ito T; Ishizu Y; Honda T; Ishikawa T; Fujishiro M
    Anticancer Res; 2020 Apr; 40(4):2283-2290. PubMed ID: 32234927
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Interstitial pneumonia suspected during regorafenib administration and exacerbated by subsequent therapy with lenvatinib for unresectable hepatocellular carcinoma.
    Kotani K; Enomoto M; Okada M; Yoshida K; Motoyama H; Fujii H; Hagihara A; Uchida-Kobayashi S; Morikawa H; Murakami Y; Tamori A; Kawada N
    Clin J Gastroenterol; 2019 Aug; 12(4):355-360. PubMed ID: 31020569
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A spontaneous rupture of lung metastasis from hepatocellular carcinoma after the introduction of lenvatinib.
    Higashino M; Sugiura R; Yamamoto Y; Naruse H; Sakamoto N
    J Gastrointestin Liver Dis; 2021 Mar; 30(1):169-170. PubMed ID: 33723551
    [No Abstract]   [Full Text] [Related]  

  • 66. Mac-2 binding protein glycosylation isomer predicts tolerability and clinical outcome of lenvatinib therapy for hepatocellular carcinoma.
    Eso Y; Nakano S; Mishima M; Arasawa S; Iguchi E; Takeda H; Takai A; Takahashi K; Taura K; Seno H
    J Hepatobiliary Pancreat Sci; 2021 Jun; 28(6):498-507. PubMed ID: 33787071
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Impact of Grip Strength in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib.
    Endo K; Kuroda H; Kanazawa J; Sato T; Fujiwara Y; Abe T; Sato H; Kooka Y; Oikawa T; Sawara K; Takikawa Y
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32756366
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Colitis induced by Lenvatinib in a patient with advanced hepatocellular carcinoma.
    Miyajima S; Tsuji K; Kito Y; Yoshida N; Matsunaga K; Tsuji S; Katayanagi K; Yonezawa M; Kubo A; Ushijima K; Minato H; Doyama H
    Clin J Gastroenterol; 2021 Feb; 14(1):187-192. PubMed ID: 33025343
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Lenvatinib Rechallenge After Ramucirumab Treatment Failure for Hepatocellular Carcinoma.
    Komatsu S; Yano Y; Kido M; Kuramitsu K; Gon H; Fukushima K; Urade T; So S; Yanagimoto H; Toyama H; Kodama Y; Fukumoto T
    Anticancer Res; 2021 Sep; 41(9):4555-4562. PubMed ID: 34475083
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effect of levocarnitine administration in patients with chronic liver disease.
    Ohashi K; Ishikawa T; Hoshii A; Hokari T; Suzuki M; Noguchi H; Hirosawa H; Koyama F; Kobayashi M; Hirosawa S; Sugiyama K; Mitobe Y; Yoshida T
    Exp Ther Med; 2020 Nov; 20(5):94. PubMed ID: 32973943
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Acute exacerbation of asthma induced by combined therapy of programmed death-1 Blocker plus lenvatinib in a patient with advanced hepatocellular carcinoma.
    Wang H; Shi J; Wang X; Zhao H; Wang H
    Eur J Cancer; 2021 Oct; 156():122-124. PubMed ID: 34428685
    [No Abstract]   [Full Text] [Related]  

  • 72. Hepatocellular Carcinoma Rupture after Introducing Lenvatinib: An Autopsy Case Report.
    Kohya R; Sugiura R; Yamamoto Y; Naruse H; Hatanaka K; Kinoshita K; Abiko S; Miyamoto S; Suzuki K; Kushibiki H; Munakata S; Shimoyama N
    Intern Med; 2023 Apr; 62(7):995-998. PubMed ID: 36047124
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Branched-chain amino acid to tyrosine ratio is an essential pre-treatment factor for maintaining sufficient treatment intensity of lenvatinib in patients with hepatocellular carcinoma.
    Eso Y; Nakano S; Mishima M; Arasawa S; Iguchi E; Takeda H; Takai A; Takahashi K; Seno H
    J Hepatobiliary Pancreat Sci; 2020 Dec; 27(12):913-921. PubMed ID: 32894808
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Can L-carnitine supplementation and exercise improve muscle complications in patients with liver cirrhosis who receive branched-chain amino acid supplementation?
    Hiraoka A; Kiguchi D; Ninomiya T; Hirooka M; Abe M; Matsuura B; Hiasa Y; Michitaka K
    Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):878-884. PubMed ID: 31150367
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The change rate in serum nitric oxide may affect lenvatinib therapy in hepatocellular carcinoma.
    Kawamura A; Uojima H; Chuma M; Shao X; Hidaka H; Nakazawa T; Take A; Sakaguchi Y; Numata K; Kako M; Nozaki A; Azuma S; Horio K; Kusano C; Atsuda K
    BMC Cancer; 2022 Aug; 22(1):912. PubMed ID: 35999529
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Leaky Gut and Severe Adverse Events in Advanced Hepatocellular Carcinoma Treated With Lenvatinib.
    Fujimoto Y; Namisaki T; Takeda S; Murata K; Enomoto M; Takaya H; Tsuji Y; Fujinaga Y; Sawada Y; Nishimura N; Kitagawa K; Kaji K; Inoue T; Kawaratani H; Moriya K; Akahane T; Mitoro A; Yoshiji H
    Anticancer Res; 2022 Oct; 42(10):4895-4905. PubMed ID: 36191983
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma.
    Shigesawa T; Suda G; Kimura M; Maehara O; Tokuchi Y; Kubo A; Yamada R; Furuya K; Baba M; Kitagataya T; Suzuki K; Ohara M; Kawagishi N; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N
    PLoS One; 2021; 16(3):e0247728. PubMed ID: 33647018
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma.
    Kuorda H; Abe T; Fujiwara Y; Okamoto T; Yonezawa M; Sato H; Endo K; Oikawa T; Sawara K; Takikawa Y
    World J Gastroenterol; 2019 May; 25(19):2365-2372. PubMed ID: 31148907
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib.
    Fujii Y; Ono A; Hayes CN; Aikata H; Yamauchi M; Uchikawa S; Kodama K; Teraoka Y; Fujino H; Nakahara T; Murakami E; Miki D; Okamoto W; Kawaoka T; Tsuge M; Imamura M; Chayama K
    J Exp Clin Cancer Res; 2021 Jun; 40(1):215. PubMed ID: 34174931
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
    Kudo M; Finn RS; Qin S; Han KH; Ikeda K; Piscaglia F; Baron A; Park JW; Han G; Jassem J; Blanc JF; Vogel A; Komov D; Evans TRJ; Lopez C; Dutcus C; Guo M; Saito K; Kraljevic S; Tamai T; Ren M; Cheng AL
    Lancet; 2018 Mar; 391(10126):1163-1173. PubMed ID: 29433850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.